Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JXJieyu XuHYHaiyan Yang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows Zanubrutinib with G-CVP safely improves outcomes in follicular lymphoma, highlighting its potential as an effective first-line therapy.

Key Points

  • This study evaluates the efficacy and safety of zanubrutinib combined with G-CVP in previously untreated patients with follicular lymphoma.
  • Retrospective analysis of untreated follicular lymphoma patients receiving the ZG-CVP regimen.
  • Patients received 6 cycles of ZG-CVP consisting of zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, and prednisone.
  • Efficacy was assessed by complete response rate and objective response rate, with safety evaluated via CTCAE criteria.
  • Of 23 patients, 95.2% achieved a complete response after 4 cycles.
  • 100% of evaluable patients who completed 6 cycles achieved complete response.
  • Adverse events included anemia in 56.5% and neutropenia in 47.8%, mostly grade 1-2.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1f2https://doi.org/10.1182/blood-2025-7103
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  2. 2Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  5. 5Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025